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 ABSTRACT  
Background:  arterial and venous complications are major causes of morbidity and mortality 
in myeloproliferative neoplasms (MPNs). MPNs patients, frequently receive heparin. 
Heparin-induced thrombocytopenia (HIT) is a rare but potentially life-threatening 
complication resulting in a severe acquired thrombophilic condition.  Patients and methods 
we carried out a retrospective analysis to evaluate occurrence of new thrombotic events 
during heparin therapy in essential thrombocythemia (ET) patients. We studied 108 ET 
patients on heparin for treatment of previous thrombotic events or in thromboprophilaxis.   
Fifty-eight of them carried JAK 2 V617F mutation while fifty patients were without V617F 
mutation.  Results:  Ten patients, among those with JAK 2 V617F mutation after a median 
of 10 days from heparin treatment presented a platelet drop, new thrombotic events and in 
10/10 cases heparin-related antibodies were found. In the other group, 2 patients (4%) 
presented a platelet drop, thrombotic manifestations and heparin related antibodies.  
Conclusions:  Our data show that HIT is more frequent, during heparin treatment, in 
patients with ET carrying V617F mutation, as compared with patients without mutations  
(P=0.029). ET with V617F mutation seems to be associated with higher risk of thrombotic 
complications during heparin treatment.  Monitoring platelet counts very closely during the 
course of heparin is essential especially in ET patients in which platelet drop may be hidden 
by constitutional thrombocytosis.  
KEY WORDS:  myeloproliferative neoplasms (MPNs); essential thrombocythemia; Heparin 
Treatment; Heparin-induced thrombocytopenia (HIT); V617F mutation.   
 INTRODUCTION 
Patients with Philadelphia chromosome negative myeloproliferative neoplasms are at 
increased risk of arterial and venous thrombosis. The cumulative incidence of all 
thromboembolic events amount to 2.5% to 5% per patient/year in Policytemia Vera ( PV) 
and to 1.9% to 3% per patient in Essential thrombocythemia (ET ) [1][2][3]. Only 30% of all 
vascular events in BCR-ABL1 negative MPNs patients are venous thromboembolism (VTE), 
while arterial thromboembolism is more frequent  [2[3] [4][5][6]. The JAK2V617F mutation, 
commonly found in MPN, correlates with several clinical and laboratory characteristics. The 
frequency of JAK2 V617F mutation for PV, idiopathic myelofibrosis (IMF), and ET is 92%, 
58%, 50% respectively [7]. The role of JAK2 V617F allele burden as risk factor for thrombosis 
in MPNs remains debated to date [8][9][10][11][12][13][14]; however, recent advances 
showed that higher JAK2 mutation allele burden (> 75%) predispose patients to higher 
thrombotic and haemorrhagic risk [15] [16]. Recently other recurrent mutations have been 
identified in MPN including the MPL W 515 L/K mutation and mutations of Calreticulin 
(CALR). MPL mutations are present in 8.5% of JAK2 V617F negative patients while CALR 
mutations in around 20-25% [18][19]. CALR mutations are associated with younger age, 
male sex, higher platelet count, lower haemoglobin level, lower leukocyte count and lower 
incidence of thrombotic events [20]. 
Because frequently MPNs patients have had previous exposure to heparin, the presence of 
heparin-related anti-platelet antibodies typical for heparin-induced thrombocytopenia 
(HIT) is one underlying possible mechanism of thrombosis despite masked normal platelet 
count.  
 HIT is an adverse drug reaction caused by immunoglobulin (Ig) G platelet-activating 
antibodies that bind to platelet factor 4/heparin (PF4/H) complexes on the surface of 
platelets [21]. Although a significant proportion of patients exposed to heparin will develop 
anti-PF4/heparin antibodies, a much smaller fraction will develop clinical features of HIT 
with overt thromboembolic manifestations (HITT). Platelet factor 4 (PF4) displaced from 
endothelial cells, or directly from the platelets, binds to heparin molecule to form an 
immunogenic complex. The anti-heparin/PF4 Ig G immune-complexes activates platelets 
through binding with the Fc gamma RII a (CD32) receptor inducing endothelial lesions. The 
resulting thrombin generation causes consumptive thrombocytopenia and can lead to 
devastating venous and arterial thromboembolic complications. Cytokines are generated 
during this process and inflammation could play an additional role in the pathogenesis of 
thromboembolic manifestations [22] [23]  
The diagnosis of HIT is generally established when a platelet drop of at least 50% occurs in 
the absence of obvious explanations for thrombocytopenia, and by demonstration of 
heparin-dependent IgG antibodies. However, HIT in the presence of normal-high platelet 
counts presents a diagnostic challenge and requires a high index of suspicion.   It has been 
suggested that the observed risk of HIT is higher in patients with MPNs. [24] [25][26][27]. 
The aim of our study is to evaluate the occurrence of new thrombotic events among patients 
with ET with JAK2 V617F mutation treated with un-fractioned (UFH) or low molecular 
weight heparin (LMWH).  
PATIENTS AND METHODS 
This retrospective analysis considered a consecutive series of ET patients exposed  to 
heparin because of  previous  thrombotic events in usual or in unusual sites or in 
thromboprophilaxis for surgery  This retrospective study lasted  from  March 2006 to March 
2017. The patients were divided into two subgroups : group 1:  ET  patients carrying JAK2 
V617F mutations;    group 2:  ET patients without JAK2 V617F mutation (control group).  
 All patients were followed in two University Hospitals.  The study was conducted 
according to the ethical principles stated in the Declaration of Helsinki, and the Institutional 
Review Board of our University Hospital approved the protocol.  
The diagnosis of ET was based on the 2008 WHO criteria [28]. All of their available medical 
charts were reviewed, and a record was made of the data relating to their clinical 
characteristics, laboratory data, and bone marrow biopsy findings at the time of the 
diagnosis of thrombotic events and/or MPN.   Informed consent to treat laboratory and 
clinical data was obtained from all individuals participants included in the study. 
Coagulation Screening 
A careful family and personal thrombotic history was collected for each patient, history of 
miscarriages and obstetrical history was collected in female’s patients.  Coagulation tests  
including  serum fibrinogen, prothrombin time (PT) and partial thromboplastin time (PTT), 
anti-thrombin III, Protein C  and S  (total and Free) and APC resistance, Leiden factor V, 
prothrombin G20210A mutations and anti-phospholipids autoantibodies were performed 
in order to rule out additional prothrombotic risks.  
  
Molecular Analysis 
The JAK2 V617F mutation was detected by means of allele-specific PCR using the protocol 
of Baxter et al. [29] and confirmed by means of direct sequencing (ABI PRISM 310 Genetic 
Analyser, Applied Biosystems, Warrington, UK) using the Big Dye Termina-tor Cycle 
Sequencing Kit (Applied Biosystems, Warrington, UK). The allele burden of the mutation 
was quantitatively analyzed using the protocol recently published by  Klampfl et al [19].  
In the JAK-2 negative group MPL/CALR mutations were detected by PCR [30] 
Thromboembolic complications 
The clinical suspicion of venous or arterial thromboembolism was confirmed by the 
following objective tests: compression ultrasound or venography in case of suspected DVT. 
Ventilation/perfusion lung scanning, spiral computed tomography (CT) or pulmonary 
angiography in case of suspected pulmonary embolism. Electrocardiography with 
enzymatic and troponin T support in case of suspected myocardial infarction, and cerebral 
CT scan or magnetic resonance imaging in case of suspected stroke.  
Diagnostic criteria for new thrombotic events consisted in: 1) onset of any group of clinical 
symptoms compatible with arterial or venous thrombosis in patients previously 
asymptomatic, subsequently confirmed by objective tests listed above 2) contralateral onset 
of DVT  in patients with confirmed ipsilateral DVT 3) non-compressibility > or = 4 mm of a 
previous normalized venous segment and enlargement of thrombus thickness > or = 2 mm 
were considered diagnostic of proximal DVT.      
Clinical Probability of HIT 
The clinical probability of HIT was defined according to the 4 T’s score proposed by Lo et 
al.[31]; a score higher than six was used to predict a high clinical likelihood of HIT.  
Development of HIT 
A platelet count was performed at baseline conditions and thereafter at least every 2 or 3 
days. The diagnosis of HIT was suspected in all cases of platelet drop of at least 50% of pre- 
treatment value, if this was confirmed by a second determination. In all patients in whom a 
likely reason for thrombocytopenia (hemodilution from fluids/blood, sepsis, disseminated 
intravascular coagulation (DIC), other drug reactions, etc.) could not be found, a blood 
sample was obtained for the subsequent determination of heparin-dependent antibodies.  
HIT diagnosis is based on the combination of a compatible clinical picture correlated with 
the presence of platelet-activating anti-PF4 antibodies (Ab).  
Laboratory determination of heparin-dependent Ig G antibodies 
Both an antigen and a functional assay were performed to detect heparin-dependent 
antibodies according to previously described methods at clinical suspicion of HIT. 
 Blood samples were collected from a brachial vein with a fine needle in sodium citrate 1:10 
(antigen assay) and without anticoagulant (functional assay). Samples were then 
centrifuged at 10 000 g for three minutes and stored at – 70°C. [32]. 
The samples were screened by an antigen assay that detects antibody mixture of IgG, IgA, 
and IgM antibodies against platelet factor 4 complexed with polyvinyl sulfonate (Genetic 
Testing Institute, Brookfield, WI).Absorbance of the substrate of alkaline phosphatase was 
measured at 405 nm. This test was followed, in case of a positive result, by the search for 
HIT antibodies of the IgG class using a single anti-IgG alkaline phosphatase conjugate Fc 
specific (Sigma Chemical, St Louis, MO). The cut-off value of optical density (OD) for the 
antibody determination was assessed using plasma samples of 43 patients who did not 
develop thrombocytopenia within 48 hours of LMWH start; the value was considered 
positive for values >0.10 OD. 
The functional test was done with a modification of the visual evaluation of heparin-
induced platelet activation (HIPA) assay.[33] on patients with clinical suspicion of HIT and 
negative OD. HIPA is a platelet-activation test in which the patient's serum is mixed with 
donor platelets in the presence of heparin. Aggregation of the donor platelets indicates the 
presence of antibodies to the heparin–PF4 complex. 
Statistical Analysis  
The study group included ET patients carrying JAK2 (V617F) mutation, and ET patients 
without JAK2 (V617F) mutation. The differences in thrombotic events during heparin 
treatment or prophylaxis between the two groups   was calculated by using the chi-square 
test. Student T test  for unpaired values was used to assess the statistical significance of the 
differences between groups. Wilcox on matched-pairs signed rank test was used to assess 
any significant changing in platelet count before and after the occurrence of HIT. To assess 
changes in platelet count we computed an index of variations by subtracting the patient’s 
platelet count after HIT from the patient’s platelet count after the first episode of 
thrombosis. Any correlation between platelet count or its changes and occurrence of HIT 
was evaluated with simple logistic regression. A P-value of < 0.05 was considered 
statistically significant.  
All the analyses were made using SPSS PC statistical package, release 20.0 (IBM SPSS  Inc, 
Chicago; IL, USA) , and statistical software R, release 3.0.0 ( R Foundation for statistical 
computing, Vienna Austria).   
 RESULTS 
Laboratory findings:  
A search for H/PF4 Abs was performed using immune and functional assays, and the 
presence of specific and platelet-activating IgG confirmed the clinical suspicion of HIT  in 
twelve patients who presented thrombosis during heparin treatment ( See table 2).   The 
patient 9 had negative OD, but the heparin-induced platelet aggregation assay (HIPA) was 
performed and  confirmed diagnosis of HIT. 
Clinical Pathological features of MPNs associated with thrombotic manifestation.  
We selected 108 patients with ET.  Fifty-eight patients carried JAK2 V617F mutation, 27 
males and 31 females who presented an unusual splanchnic vein thrombosis or thrombosis 
in usual or /unusual site needing heparin treatment. Median age was 41 years (range 16-65).  
Fifty ET patients not carrying JAK2 V617F mutation, exposed to heparin for thrombosis 
served as control group.  Coagulation screening was negative for 104 patients, while two 
patients presented Leiden factor V mutation and two patients presented prothrombin 
G20210A mutations. Molecular analysis showed JAK2 V617F mutation in 58 patients, JAK2 
median allele burden 27.7% range (4.8-97.0).  The main clinical-pathological features of the 
58 study patients and 50 controls are summarized in Table 1.  The two groups did not 
significantly differed for sex, age, duration of follow up, reasons for heparin treatment, 
initial platelet count was higher in JAK2 V617F mutation positive patients.  
Thrombotic manifestations In the group I all patients presented usual site or unusual site 
thrombotic complication requiring heparin treatment, or were on heparin prophylaxis for 
surgery: ten patients (17.2%) had cranial sinus vein thrombosis; four patients (6.9%) had 
coronary artery disease.  Four patients (6.9 %) had mesenteric and portal vein thrombosis, 
five patients (8.6%) had Budd Chiari syndrome, six patients (10,3 %) had ischemic stroke, 
seven patients (12 %) had  deep vein thrombosis, twenty-two (38 %) were on heparin 
prophylaxis for surgery. 
Forty-six patients (79.3%) were treated with low molecular weight heparin, while 12 (20,6%) 
received un-fractioned heparin. During heparin treatment, at a median of 7.5 days (range 5-
10 days) after beginning of heparin treatment, 10 patients developed new thrombotic 
manifestations characterized by rapid onset of symptoms. Two patients presented new 
neurological symptoms while receiving heparin, one for DVT and one for splacnic vein 
thrombosis. One patient presented arterial limb ischemia, one patient presented sudden 
headache and CT scan documented sinus venous thrombosis, two patients during heparin 
treatment presented central line venous thrombosis , one patient presented hypotension and 
sudden syncope together with dyspnoea and CT scan documented bilateral pulmonary 
embolism. Three patients presented unusual splacnic vein thrombosis.  
Of the ET patients with JAK2 V617F mutation who presented thrombosis and heparin 
dependent antibodies during exposure to heparin, 3 patients were on un-fractioned heparin 
and 7 patients received low molecular weight heparin. In the control group, the two patients 
with HITT were on LMWH. 
All patients had a platelet drop, and in all cases, no alternative causes of thrombocytopenia 
were found. Platelet drop and thrombotic manifestations were concomitant. Seven of ten 
patients who had thrombotic manifestations had previous exposure to heparin. All patients 
treated with UFH were in therapeutic range at the time of onset of thrombotic manifestation.  
Heparin-related antibodies were found in ten patients with heparin-related thrombotic 
complications in the group I and in two patients in the control group. Table 2 reports clinical 
characteristics of ten patients with MPNs and new thrombotic events during heparin 
treatment. In the control group (consisting of 50 patients with ET without JAK2 V617F 
mutation undergoing UFH or LMWH) , 2 of them presented thrombotic manifestation 
consisting in cerebral thrombosis and in acute coronary syndrome, platelet drop and 
heparin-dependent Ig G antibodies were documented. Statistical analysis showed a 
significant increase of thrombotic manifestation in ET patients carrying JAK2 V617F 
mutation compared with ET patients without the mutation. (P= 0.029).  
 
DISCUSSION.  
The study presented here is aimed to determine if the thrombosis or recurrence of 
thrombosis, that arise in the course of heparin treatment in patients with ET are due, at least 
in part, to the heparin–induced thrombocytopenia.  Patients with MPN are prone to develop 
thrombosis being this the major cause of morbidity and mortality among MPN patients. 
UFH and LMWH therapy are associated with a high rate of drug-related problems and side 
effects due to either their inherent pharmacological properties or human errors. 
Thrombocytopenia, bleeding events, and osteopenia are the 3 most common drug-related 
problems associated with unfractionated heparin and LMWH therapy [34].  Beside 
hemorrhagic complications also thrombotic events are described while patients assume 
unfractionated heparin or LMWH.  HIT occurs in 3 to 5 percent of patients who receive 
intravenous unfractionated heparin compared to the 0.5 percent incidence rate with 
subcutaneous LMWH, catheter flushes, and even the minuscule amounts of heparin that 
leaks from coated catheters [35]. Absolute risk for HIT was only 0.2% with LMWH and was 
2.6% with unfractionated heparin.[36] HIT can precipitate an extreme prothrombotic 
diathesis known as HITT, resulting in venous or arterial thromboembolism  in 50 percent of 
patients.  The pathophysiology of HIT may be different in UFH from in LMWH. The smaller 
molecule size of LMWH at least in part determines its affinity for PF4, as has been shown 
experimentally.  Presumably, this makes LMWH less likely to induce HIT than the larger 
unfractionated heparins. Nevertheless HITT, although rare is also seen in patients treated 
with LMWH . The interesting finding, observed in our case series that 9/12 patients 
developed HITT during therapy or prophylaxis with LMWH may be explained with the fact 
that actually UFH is reserved only to patients with severe renal failure, or to patients at high 
risk for bleeding complications or to candidates to invasive procedures. LMWH is largely 
preferred in all other patients both for prophylaxis and for therapy of thrombotic 
complications. 
Anecdotal data on relationship between HIT and MPNs are reported [26], but few studies 
have systematically approached the problem. [27][25].  Thus to differentiate if a thrombotic 
event, occurring during heparin treatment, may be related to HIT  or due to thrombotic 
complication of MPNs as natural course of disease  may be very challenging. The masked 
normal platelet count, in a subset of patients with thrombocytosis, can further accentuate 
the problem hiding a heparin- induced thrombocytopenia. For these reasons, the real 
incidence of heparin-induced thrombocytopenia in the pathogenesis of new thrombotic 
events in the setting of patients of MPNs treated with heparin remains unclear and might 
be under-estimated. Spectre et al  reported three patients with MPNs who developed HIT; 
all presented with a relative fall of platelet counts (although without an absolute 
thrombocytopenia), thrombosis or skin necrosis and a positive test for HIT antibodies 
(particle gel immunoassay)[37]. Bovet et al. [25] highlighted that the observed risk of HIT in 
MPNs was 10 times higher than in general population. Since HIT occurs in approximately 
1 in 5000 hospitalized patients [38] the incidence of HIT is relatively high in our study 
population, confirming the suspect that HIT may be more frequent in patients with MPNs.  
The same authors hypothesize that platelet activation markers have been reported in ET 
patients, which could explain the predisposition for HIT in these patients. High PF4 levels 
have been observed in ET patients, thus leading to the formation of PF4/heparin complexes, 
which predispose MPNs patients to HIT [39]. In the same way, HIT has already been 
reported in PV, thus reinforcing a potential link between MPNs and HIT.  In our series, we 
have evaluated 58 patients affected by MPNs with JAK 2 V617F mutation, which, for 
prophylaxis or for treatment of thrombotic events, were exposed to any heparin treatment 
(UFH or LMWH) and 50 patients with ET exposed to any type of heparin without JAK 2 
V617F mutation.  Ten of these patients (17.2%) presented a new thrombotic event after 
exposure to heparin in the group one.  Only 2 patients in the control group presented 
thrombotic events during heparin treatment. Considering the clinical manifestations 
(sudden thrombotic events in- patient’s previously asymptomatic), the high clinical 
probability, the presence of Ig G heparin dependent autoantibodies and the platelet drop, 
the clinical picture is highly consistent with diagnosis of heparin-induced 
thrombocytopenia. The time from heparin exposure and platelet drop corroborates the 
diagnosis of HIT. It should be considered that platelet drop might be, in patients with 
thrombotic events, or thrombotic recurrence, a mere platelet consumption, but all patients 
in our series had heparin related platelet antibodies suggesting an immune-mediated 
platelet drop like HITT.  Statistical analysis showed that the prevalence of thrombotic 
events, in ET patients exposed to heparin is significantly related with the presence of 
JAK2 V617F mutation suggesting that the presence of such mutation could be a risk factor 
both for thrombosis and for HITT. The JAK2 V617F mutation unequivocally divides the 
disease into two subtypes, patients with V617F mutations have a pattern of disease 
characterized by significantly increased haemoglobin, bone marrow erythropoiesis and 
granulopoiesis, more venous thrombosis, and a higher rate of polycythaemic 
transformation than those without the mutation [40].   Rumi et al. [14] have recently 
suggested that JAK2 V617F mutation represent a strong additional risk factor for 
thromboembolic events in patients with MPNs as compared with patients with CALR 
mutation who rarely develop  anemia, thrombocytopenia, marked leukocytosis and 
thrombosis .  
Limitations 
Our study has not the statistical power to evaluate in absolute  the prevalence of HIT in 
patients with MPNs exposed to heparin treatment due to  the rarity of phenomenon  , it is a 
retrospective study,   but strongly suggest that HIT may play a role, in the pathogenesis of 
thrombosis or recurrence of thrombosis that arise in the course of heparin treatment in 
patients with JAK 2 mutated myeloproliferative neoplasms. Essential thrombocythemia 
carrying JAK2 V617F mutation seems to be associated with higher risk of thrombotic 
complications during heparin treatment and this finding should be confirmed in wider 
studies due to the rarity of the disease. 
Conclusions 
Our data show that HIT is more frequent, during heparin treatment,  in patients with ET 
carrying JAK2 V617F mutation.  ET and JAK2V617F mutation seems to be associated with 
higher risk of thrombotic complications during heparin treatment. 
This paper suggests the relationship between heparin-induced thrombocytopenia with 
thrombosis (HITT) and thrombotic events during heparin treatment in the setting of patients 
with ET carrying JAK 2 V617F mutation. This observation  illustrates the need to monitor 
platelet counts very closely during the course of heparin—even subcutaneous heparin—
therapy especially in patients in which platelet drop may be hidden by constitutional 
thrombocytosis such as in ET patients. HIT can lead to HITT, which can cause severe harm. 
The early identification of HIT and subsequent termination of heparin therapy can prevent 
complications especially in a setting of patients prone to thrombotic complications.  
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Clinical Characteristic of patients with Essential Thrombocythemia (ET) and heparin 
induced thrombocytopenia according to JAK2 (V617F) Mutation.  
                                                                                                                                                                        
               ET    JAK2             ET    JAK2        P value 
        mutation positive   mutation  negative            
N                                             58 (100%)                                   50 (100%)          
Male/Female  27/31 27/23 ns 
Median age 
( Years/range) 
41  ( 16-65) 43  (18-67) ns 
Median Follow up 
(Years) 
4 (1-5) 4(1-5) ns 
Low molecular 
weight heparin  
46 (79%) 37 (74%) ns 
MPL mutation Not detected 2 (4%) na 
CALR mutation Not detected 10 (20%) na 
Triple negative 
patient 
 7 (14%) na 
Prior Heparin 
treatment 
11 (19%) 9 (18%) ns 
Cytoreduction with 
Hydroxyurea  
16 (27.5%)  10 (20%) ns 
Cytoreduction with 
Interferon 
1  (1.7%) 1 (2%) ns 
Reason for heparin 
treatment 
   
Cranial sinus 
Thrombosis  
10 ( 17,2 %) 8 (16%) ns 
Coronary artery 
Disease 
4 (6.9%) 2 (4%) ns 
Mesenteric and 
portal vein 
thrombosis  
4 ( 6.9%) 2 (4%9 ns 
Surgery Prophylaxis 22 (38%)                                  25 (50%)             ns 
Budd Chiari 
Syndrome 
5 (8.6 %)                                  3 (6%)     ns 
Deep vein 
thrombosis 
7(12%) 4 (8%) ns 
Initial platelet count 
(x 10 9/L) mean  
1076                                                        980 p< 0.001    
Total   10 (17.2%) 2 (4%) P=0.029 
New neurological 
signs 
 
2 of 10 (20%) 1 of 2  
Arterial limb 
ischemia 
 
1 of 10 (10%)   
Sinus vein 
thrombosis 
1 of 10 (10%)   
Pulmonary 
embolism 
1 of 10 (10%)   
Central vein 
thrombosis  
2 of 10 (20%)   
Unusual splanchnic 
vein thrombosis 
 
3 of 10 (30%) 1 of 2  
Low Molecular 
weight heparin 
while                
thrombosis 
7 2  
 
Ns: not significant, na: not applicable 
 
 Patient n/ 
gender 
Type of 
Myeloproliferative 
disease 
First thrombosis Second 
thrombosis 
 Additional 
prothrombotic risk 
factor/ JAK 2 
status  
Type of 
Heparin 
Anticoagulant 
after heparin 
withdrawal 
Days 
elapsing 
between 
1st and 2nd 
thrombosis 
Platelets at 
1st 
thrombosis, 
109/l 
Platelet 
nadir, 
!109/l 
Total 4 
T’s score 
H/PF4 
Ab IgG 
OD 
1/F ET Coronary artery 
disease 
ictus None/ V617F LMWH Lepirudin/oral 
anticoagulants 
14 456 90 7 > 2 
2/F ET Mesenteric 
thrombosis  
ictus F V Leiden/ V617F UFH Lepirudin/oral 
anticoagulants 
12 729 300 8 > 2 
3/F ET Coronary artery 
disease 
Arterial 
limb 
ischemia 
None/ V617F LMWH Lepirudin/oral 
anticoagulants 
10 859 268 8 > 2 
4/M ET Portal vein 
thrombosis 
Sinus vein 
thrombosis 
none V617F LMWH Lepirudin/oral 
anticoagulants 
12 426 87 8 > 2 
5/M ET Portal vein 
thrombosis 
Pulmonary 
embolism 
none V617F LMWH Lepirudin/oral 
anticoagulants 
12 830 422 7 > 2 
6/F ET Coronary artery 
disease 
Central 
vein 
thrombosis 
None/ V617F UFH Lepirudin/oral 
anticoagulants 
15 236 64 7 > 2 
7/M ET Coronary artery 
disease 
Central 
vein 
thrombosis 
Prothrombin 
G20210A 
mutations/ V617F 
LMWH Lepirudin/oral 
anticoagulants 
14 657 275 7 > 2 
8/F ET DVT Splacnic 
vein 
thrombosis 
None/ V617F UFH Fondaparinus 15 67 12 8 > 2 
9/F ET Surgery 
prophylaxis 
Splacnic 
vein 
thrombosis 
None/ V617F LMWH oral 
anticoagulants 
8 230 87 7 o.10 
10/M ET DVT Splacnic 
vein 
thrombosis 
None/ V617F LMWH Fondaparinus 12 342 67 7 > 2 
11/M ET DVT Ictus None/negative  LMWH Lepirudin/oral 
anticoagulants 
15 360 78 7 > 2 
 
 
 
Biological and Clinical Features of 12 patients affected by Essential Trombocytopenia (ET)  who presented thrombotic complications during heparin treatment 
DVT. Deep vein thrombosis, LMWH. Low molecular weight heparin. UFH.: Unfractioned heparin.  
 
 
12/F ET Surgery 
prophylaxis 
Arterial 
limb 
ischemia 
None/negative LMWH Lepirudin/oral 
anticoagulants 
16 398 58 7 > 2 
